EGFR-TKI Clinical Trials

6 recruitingLast updated: July 25, 2026

There are 6 actively recruiting egfr-tki clinical trials across 4 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3. Top locations include Amiens, France, Annecy, France, Aurillac, France. Updated daily from ClinicalTrials.gov.


EGFR-TKI Trials at a Glance

6 actively recruiting trials for egfr-tki are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Amiens, Annecy, and Aurillac. Lead sponsors running egfr-tki studies include China Medical University Hospital, Federation Francophone de Cancerologie Digestive, and Queen Mary Hospital, Hong Kong.

Browse egfr-tki trials by phase

Treatments under study

About EGFR-TKI Clinical Trials

Looking for clinical trials for EGFR-TKI? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new EGFR-TKI trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about EGFR-TKI clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Not Applicable

Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)Antineoplastic Agents, ImmunologicalVEGFR-TKI
Federation Francophone de Cancerologie Digestive300 enrolled83 locationsNCT07124858
Recruiting
Phase 1Phase 2

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Non-small Cell Lung CancerEGFR-TKI Resistant MutationEGFR Gene Mutation
China Medical University Hospital20 enrolled1 locationNCT06071013
Recruiting

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

Lung Cancer (Non-Small Cell)Circulating Tumor DNAEGFR-TKI Resistant Mutation+2 more
Second Xiangya Hospital of Central South University210 enrolled1 locationNCT05598528
Recruiting
Phase 3

Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia

ParonychiaEGFR-TKIALK-TKI
Queen Mary Hospital, Hong Kong40 enrolled1 locationNCT06643416
Recruiting
Phase 2

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung CancerEGFR-TKI Resistant MutationEGFR Activating Mutation+1 more
Tianjin Medical University Cancer Institute and Hospital32 enrolled1 locationNCT06363734
Recruiting

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

Non-small Cell Lung Cancer (NSCLC)EGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation+2 more
Sun Yat-sen University1,000 enrolled1 locationNCT01994057